HCPCS Level IItemporaryActive
Q0180
Dolasetron mesylate oral
BETOS: O1D
Effective: 1998-04-01
Referenced in 1 policies
Description
Dolasetron mesylate, 100 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 24 hour dosage regimen
Medicare Fee Schedule
2026 Medicare Physician Fee Schedule national payment rates
Statutory Exclusion
This code has a statutory exclusion from Medicare coverage.
Coverage Policies